CYCLACEL PHARMACEUTICALS 6%

CYCLACEL PHARMACEUTICALS 6% CONVERTIBLE EXCHANGEABLE PREFERRED

STOCKHOLDERS REQUEST SPECIAL MEETING TO ELECT DIRECTORS

BERKELEY HEIGHTS, NJ August 13, 2010 Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC ) (Nasdaq:

CYCCP), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle

control for the treatment of cancer and other serious disorders (the Company ), today reported that it has received a

request from a holder of at least 10% of its 6% Convertible Exchangeable Preferred Stock (the Preferred Stock ) that

the Company call a special meeting of its holders of Preferred Stock to elect two directors to fill the vacancies on

the Company s board of directors. The vacancies were created pursuant to the terms of the Certificate of Designations

governing the Preferred Stock, which states that if the Company had not paid the dividends on its Preferred Stock for

six quarterly periods, the number of director positions on the Company s board of directors automatically increases by

two. This occurred as of August 2, 2010.

The holders of the Preferred Stock, voting as a separate class, are entitled to elect two directors to fill these two

vacancies at the Company s next stockholders meeting and at each annual stockholder s meeting thereafter until the

dividends are paid in full. Because the right to elect directors accrued to the holders of the Preferred Stock more

than 90 days before the next annual meeting of stockholders, the Company has established October 4, 2010 as the date

for a meeting of the Company s holders of Preferred Stock. Holders of record of the Preferred Stock as of the close of

business on September 15, 2010, will be entitled to vote at such meeting. The Company expects to mail the notice of

meeting and proxy statement to the holders of Preferred Stock at a later date.

Pursuant to the Company s bylaws, any holder of at least 10% of the issued and outstanding Preferred Stock has the

right to nominate directors to fill the two director positions, which nominations must be received by the Company s

Secretary prior to the close of business on August 23, 2010. The Company s bylaws require that nominations be in

writing and include all information required by Regulation 14A promulgated under the Securities Exchange Act of 1934,

as amended. In addition, any nomination must include the nominee s written consent to be named in the Company s proxy

statement as a nominee and his or her agreement to serve as a director, if elected. The Company s bylaws also require

that certain information be provided with respect to the stockholder making such nomination. Failure to follow the

procedures set forth in the Company s bylaws will result in the nomination being declared defective.

In general, the Company s directors should satisfy the independence, diversity and other corporate governance criteria

of the NASDAQ Stock Market, Inc. and the Securities and Exchange Commission, and should have skills and experience that

will complement the Company s needs.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control

for the treatment of cancer and other serious disorders. Three product candidates are in clinical development:

Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer.

Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the

treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. CYC116, an

Aurora kinase and VEGFR2 inhibitor, is in a Phase 1 trial in patients with solid tumors. Cyclacel s ALIGN

Pharmaceuticals subsidiary markets directly in the U.S. Xclair Cream for radiation dermatitis, Numoisyn Liquid and

Numoisyn Lozenges for xerostomia. Cyclacel s strategy is to build a diversified biopharmaceutical business focused in

hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug

candidates. Please visit www.cyclacel.com for additional information.

Forward-looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause

actual results to be materially different from historical results or from any future results expressed or implied by

such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the

efficacy, safety, and intended utilization of Cyclacel s product candidates, the conduct and results of future clinical

trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering

activities. Factors that may cause actual results to differ materially include the risk that product candidates that

appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or

later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated

with reliance on outside financing to meet capital requirements, and the risks associated with reliance on

collaborative partners for further clinical trials, development and commercialization of product candidates. You are

urged to consider statements that include the words may, will, would, could, should, believes, estimates,

projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal, or

the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and

description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form

10-K and other periodic and current filings that have been filed with the Securities and Exchange Commission and are

available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and

we assume no obligation to update any forward-looking statements, whether as a result of new information, future events

Contact for Cyclacel Pharmaceuticals, Inc.

Corey Sohmer, (908) 517-7330

of Cyclacel Pharmaceuticals, Inc. Numoisyn and Xclair are trademarks of Sinclair Pharma plc.